

# **Data Sheet**

 Product Name:
 JNJ-10198409

 Cat. No.:
 CS-W011982

 CAS No.:
 627518-40-5


 Molecular Formula:
 C<sub>18</sub>H<sub>16</sub>FN<sub>3</sub>O<sub>2</sub>

Molecular Weight: 325.34

Target: PDGFR

Pathway: Protein Tyrosine Kinase/RTK

**Solubility:** DMSO: 83.33 mg/mL (256.13 mM; Need ultrasonic)



## **BIOLOGICAL ACTIVITY:**

JNJ-10198409 is a relatively selective, orally active, and ATP competitive **PDGF-RTK** (platelet-derived growth factor receptor tyrosine kinase) inhibitor ( $IC_{50}$ =2 nM). It is a dual-mechanism, antiangiogenic, and tumor cell antiproliferative agent. JNJ-10198409 has good activity against **PDGFR-** $\beta$  kinase ( $IC_{50}$ =4.2 nM) and **PDGFR-** $\alpha$  kinase ( $IC_{50}$ =45 nM) $^{[1][2]}$ . In Vitro: JNJ-10198409 has potent antiproliferative activity in six of eight human tumor cell lines ( $IC_{50}$ <0.033  $\mu$ M) and is a potent inhibitor of the c-Abl kinase ( $IC_{50}$ =22 nM) $^{[1][2]}$ .

### References:

[1]. D'Andrea MR, et al. Validation of in vivo pharmacodynamic activity of a novel PDGF receptor tyrosine kinase inhibitor using immunohistochemistry and quantitative image analysis. Mol Cancer Ther. 2005 Aug;4(8):1198-204.

[2]. Ho CY, et al. (6,7-Dimethoxy-2,4-dihydroindeno[1,2-c]pyrazol-3-yl)phenylamines: platelet-derived growth factor receptor tyrosine kinase inhibitors with broad antiproliferative activity against tumor cells. J Med Chem. 2005 Dec 29;48(26):8163-73.

#### **CAIndexNames:**

Indeno[1,2-c]pyrazol-3-amine, N-(3-fluorophenyl)-1,4-dihydro-6,7-dimethoxy-

#### **SMILES:**

COC1=CC2=C(C=C1OC)CC3=C2NN=C3NC4=CC=CC(F)=C4

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 610-426-3128 Fax: 888-484-5008 E-mail: sales@ChemScene.com

Address: 1 Deer Park Dr., Suite Q., Monmouth Junction, NJ 08852, USA

Page 1 of 1 www.ChemScene.com